People · Operator
Named in public records as an officer, director or promoter · active 2013–2015 · Pharmaceuticals, Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Turing Pharmaceuticals AG | — | Pharmaceuticals | Series C | $153.0M | $3.2B | 2015 |
| Retrophin, Inc. | — | Biotechnology | Series B | $24.9M | $988.9M | 2013 |
| Kindly, Inc | — | Other Technology | Pre-Seed | $500K | $21.2M | 2015 |
Martin Shkreli at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Martin Shkreli on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Harrison | 1 | 8 |
| Ron Tilles | 1 | 3 |
| Jordan Walker | 1 | 2 |
| Marc Panoff | 1 | 2 |
| Stephen Aselage | 1 | 2 |
| Walter Blum | 1 | 1 |
| Howard Dorfman | 1 | 1 |
| Horacio Plotkin | 1 | 1 |
| Steve Richardson | 1 | 1 |
| Gergely Kucsan | 1 | 1 |
| Alan Geller | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.